(Total Views: 481)
Posted On: 08/19/2025 7:08:36 AM
Post# of 156186
Re: KenChowder #155920
I'd go along with that Ken, but tell me then, how is it that they justify to their own shareholders dolling out $2 / share for the 50 million UWS has proposed.
CytoDyn isn't going to sell off every single share they have of the 187 million to raise $100M.
If there is no proof yet available, is some sort of Bridge Financing set up? Some sort of Interim Alliance created? An Up-Front Deal? Early Surrogate Endpoints are probably at play and many can be obtained fairly soon.
The pharmacodynamics of Leronlimab means that the data can emerge early in the clinical process. Both companies are keenly interested in this data. It is as if they are already partnered. This means that the data is partnership-driven. This timeline then would bridge the company to a deal, additional financing, or more time—without requiring fully, the completion of the CRC trial or waiting for the outcomes of the Rollover cohorts.
CytoDyn isn't going to sell off every single share they have of the 187 million to raise $100M.
If there is no proof yet available, is some sort of Bridge Financing set up? Some sort of Interim Alliance created? An Up-Front Deal? Early Surrogate Endpoints are probably at play and many can be obtained fairly soon.
The pharmacodynamics of Leronlimab means that the data can emerge early in the clinical process. Both companies are keenly interested in this data. It is as if they are already partnered. This means that the data is partnership-driven. This timeline then would bridge the company to a deal, additional financing, or more time—without requiring fully, the completion of the CRC trial or waiting for the outcomes of the Rollover cohorts.
(11)
(0)
